[SUPERMX] QoQ Quarter Result on 30-Sep-2021 [#1]

Stock
[SUPERMX] SUPERMAX CORPORATION BHD
Announcement Date
19-Nov-2021
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2022
Quarter
30-Sep-2021 [#1]
Profit Trend
QoQ- -33.4%
YoY- -19.12%
Quarter Report
Latest QR
Upcoming QR
SUPERMX's Result
SUPERMX's Financial Summary
View:
Show?
Quarter Result
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Revenue 300,226 407,799 523,542 1,455,660 1,875,482 1,937,516 1,998,645 -71.83%
PBT 29,174 18,280 91,946 930,851 1,230,578 1,342,294 1,397,240 -92.47%
Tax 3,107 -2,470 -35,288 -264,524 -218,958 -319,967 -317,540 -
NP 32,281 15,810 56,658 666,327 1,011,620 1,022,327 1,079,700 -90.42%
-
NP to SH 33,054 13,009 47,841 638,524 958,714 1,005,212 1,059,463 -90.15%
-
Tax Rate -10.65% 13.51% 38.38% 28.42% 17.79% 23.84% 22.73% -
Total Cost 267,945 391,989 466,884 789,333 863,862 915,189 918,945 -56.12%
-
Net Worth 4,811,818 4,772,629 4,921,161 4,958,201 4,724,569 4,090,149 3,244,657 30.13%
Dividend
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Div 79,315 79,104 - 129,795 389,387 336,531 97,854 -13.10%
Div Payout % 239.96% 608.07% - 20.33% 40.62% 33.48% 9.24% -
Equity
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Net Worth 4,811,818 4,772,629 4,921,161 4,958,201 4,724,569 4,090,149 3,244,657 30.13%
NOSH 2,720,616 2,720,616 2,720,616 2,720,616 2,720,616 2,720,616 2,720,616 0.00%
Ratio Analysis
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
NP Margin 10.75% 3.88% 10.82% 45.77% 53.94% 52.76% 54.02% -
ROE 0.69% 0.27% 0.97% 12.88% 20.29% 24.58% 32.65% -
Per Share
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 11.36 15.47 20.00 56.07 72.25 74.85 77.61 -72.32%
EPS 1.25 0.49 1.83 24.60 36.93 38.83 41.14 -90.32%
DPS 3.00 3.00 0.00 5.00 15.00 13.00 3.80 -14.61%
NAPS 1.82 1.81 1.88 1.91 1.82 1.58 1.26 27.86%
Adjusted Per Share Value based on latest NOSH - 2,720,616
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
RPS 11.75 15.96 20.50 56.98 73.42 75.85 78.24 -71.84%
EPS 1.29 0.51 1.87 25.00 37.53 39.35 41.47 -90.17%
DPS 3.10 3.10 0.00 5.08 15.24 13.17 3.83 -13.18%
NAPS 1.8837 1.8683 1.9265 1.941 1.8495 1.6012 1.2702 30.13%
Price Multiplier on Financial Quarter End Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 -
Price 0.875 1.18 1.47 2.39 3.30 3.81 6.01 -
P/RPS 7.71 7.63 7.35 4.26 4.57 5.09 7.74 -0.25%
P/EPS 69.99 239.18 80.43 9.72 8.94 9.81 14.61 184.99%
EY 1.43 0.42 1.24 10.29 11.19 10.19 6.85 -64.90%
DY 3.43 2.54 0.00 2.09 4.55 3.41 0.63 210.44%
P/NAPS 0.48 0.65 0.78 1.25 1.81 2.41 4.77 -78.45%
Price Multiplier on Announcement Date
30/06/22 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 CAGR
Date 22/08/22 25/05/22 22/02/22 19/11/21 26/08/21 05/05/21 29/01/21 -
Price 0.775 1.03 1.09 1.73 3.08 5.57 6.80 -
P/RPS 6.82 6.66 5.45 3.09 4.26 7.44 8.76 -15.40%
P/EPS 61.99 208.77 59.64 7.03 8.34 14.34 16.53 141.96%
EY 1.61 0.48 1.68 14.22 11.99 6.97 6.05 -58.72%
DY 3.87 2.91 0.00 2.89 4.87 2.33 0.56 264.09%
P/NAPS 0.43 0.57 0.58 0.91 1.69 3.53 5.40 -81.57%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment